SCHEMBL4477475

SCHEMBL4477475

O=C1CC2CCC(C2)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2601760 0.86 SMN1; SMN2 (0.36)
SCHEMBL31232833 0.85 SMN1; SMN2 (0.42)
SCHEMBL1142002 0.79 CA1 (0.43)
SCHEMBL26845566 0.68
SCHEMBL22821367 0.67 MEN1 (0.31)
SCHEMBL13591418 0.67 CA1 (0.40)
SCHEMBL11772819 0.66 CA1 (0.36)
SCHEMBL564510 0.66 CA1 (0.48)
SCHEMBL13028433 0.66
SCHEMBL6467930 0.66 CA1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720072-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-04-08 EP disclosed
US-20260078133-A1 RAS INHIBITORS Revolution Medicines, Inc. 2026-03-19 US disclosed
US-12209072-B2 Cyclopentyl acids as LPA antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2025-01-28 US disclosed
WO-2024249299-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2024-12-05 WO disclosed
CN-117500802-A LACTIVICIN compounds, their preparation and their use as antibacterial agents 费多拉制药有限公司 2024-02-02 CN disclosed
EP-3852746-B1 CYCLOPENTYL ACIDS AS LPA ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-03-29 EP disclosed
US-10710959-B2 Sulfide alkyl compounds for HBV treatment NOVIRA THERAPEUTICS, INC. (US) 2020-07-14 US disclosed
EP-3227262-B1 SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT NOVIRA THERAPEUTICS INC (US) 2020-05-13 EP disclosed
US-20190202780-A1 SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT NOVIRA THERAPEUTICS, INC. 2019-07-04 US disclosed
US-10196351-B2 Sulfide alkyl compounds for HBV treatment NOVIRA THERAPEUTICS, INC. (US) 2019-02-05 US disclosed
WO-2005000305-A1 3-AMINOPIPERIDINES AND 3-AMINOQUINUCLIDINES AS INHIBITORS OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2005-01-06 WO disclosed
WO-2005000811-A1 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2005-01-06 WO disclosed
US-6710188-B2 VINYL COPOLYMER HAVING 3-OXO-4-OXABICYCLO(3.2.1)OCTANE-2-YL GROUP NEC CORPORATION (JP) 2004-03-23 US disclosed
US-20030224297-A1 Chemically amplified resist, polymer for the chemically amplified resist, monomer for the polymer and method for transferring pattern to chemically amplified resist layer NEC CORPORATION 2003-12-04 US disclosed
US-6639084-B2 Comprises vinyl polymer having 3-oxo-4-oxabicyclo(3.2.1) octane-2-yl group; sensitive to far-ultraviolet light; imaging; for use with semiconductor wafers; improved resistance against dry etching and adhesion to substrates NEC CORPORATION (JP) 2003-10-28 US disclosed
US-4501687-A ETHERS OR ESTERS THEREOF, IMPARTING PLEASANT ODOR ROUSSEL UCLAF (FR) 1985-02-26 US disclosed
US-4447428-A BRONCHODILATOR, ANTICOAGULANTS GLAXO GROUP LIMITED (GB) 1984-05-08 US disclosed
US-4409213-A B-SIDE CHAIN ATTACHED THRU AMINO GROUP; BRONCHODILATORS, ANTICOAGUANT GLAXO GROUP LIMITED (GB) 1983-10-11 US disclosed
US-4265891-A PROSTAGLANDINS, BRONCHODILATORS, PLATELET AGGREGATION INHIBITORS GLAXO GROUP LIMITED (GB) 1981-05-05 US disclosed
US-4148807-A 2-Oxabicyclo[3.2.1]octan-3-ones SANDOZ LTD. (CH) 1979-04-10 US disclosed